TY - JOUR AU - Santoni-Rugiu, Eric PY - 2019 TI - Clinical outcomes provide new insights into transformation to small-cell lung cancer of pulmonary EGFR-mutant adenocarcinoma JF - Precision Cancer Medicine; Vol 2 (March 2019): Precision Cancer Medicine Y2 - 2019 KW - N2 - Despite very high response rate (RR) and significant clinical benefit of EGFR-tyrosine-kinase inhibitors (TKIs) in patients with advanced EGFR -mutated ( EGFR M+) non-small cell lung cancer (NSCLC) of adenocarcinoma (LAC) type, virtually all cases become resistant to these drugs with a median progression-free survival (PFS) of 9–13 months. UR - https://pcm.amegroups.org/article/view/4920